GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-29 22:10 |
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décemb…
|
French | 172.5 KB | ||
| 2024-01-15 22:10 |
GENFIT annonce son calendrier financier pour 2024
|
French | 126.3 KB | ||
| 2024-01-15 22:10 |
GENFIT Announces 2024 Financial Calendar
|
English | 332.7 KB | ||
| 2024-01-11 22:10 |
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Indu…
|
French | 376.7 KB | ||
| 2024-01-11 22:10 |
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commer…
|
English | 589.0 KB | ||
| 2023-12-08 07:55 |
GENFIT : Perspectives 2024 actualisées suite à la validation des dépôts de dema…
|
French | 575.2 KB | ||
| 2023-12-08 07:55 |
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Prim…
|
English | 586.4 KB | ||
| 2023-12-07 11:15 |
Ipsen confirms U.S. FDA grants priority review for New Drug Application for ela…
|
English | 346.8 KB | ||
| 2023-12-07 11:15 |
Ipsen confirme la décision de la FDA d'accorder un examen prioritaire pour le d…
|
French | 181.4 KB | ||
| 2023-12-06 17:30 |
GENFIT annonce une publication dans le Journal of Hepatology sur la performance…
|
French | 199.4 KB | ||
| 2023-12-06 17:30 |
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Perfo…
|
English | 192.9 KB | ||
| 2023-11-16 22:10 |
GENFIT dévoile sa stratégie de développement dans l’ACLF lors de son « ACLF Day…
|
French | 236.7 KB | ||
| 2023-11-16 22:10 |
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Live…
|
English | 233.9 KB | ||
| 2023-11-13 22:30 |
GENFIT : Les résultats de l’essai pivot de Phase III ELATIVE® d’Ipsen avec élaf…
|
French | 286.4 KB | ||
| 2023-11-13 22:30 |
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in…
|
English | 216.4 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
